Stockreport

Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results [Yahoo! Finance]

Vir Biotechnology, Inc.  (VIR) 
PDF – Two additional hepatitis program data readouts on track for the fourth quarter 2024 – – $1.51 billion in cash, cash equivalents and investments as of March 31, 2024 [Read more]